Navigation Links
UPCARE Technology to Share the Secrets of its Parent's Success in Lab Outreach
Date:10/9/2007

ll spectrum of what is needed for successful lab outreach, from planning to implementation and operation.

UPCARE E2E planning services include market analysis, organization readiness assessment and program design. Implementation services include process redesign and implementation, and outreach software installation, training and integration. UPCARE Technology's operational consulting services include on-site support to assist in marketing, sales and program management. For existing outreach programs, UPCARE Technology will conduct a performance review and offer recommendations for improvement and assistance in implementing them.

Jim Sundberg, CEO of UPCARE Technology said, "We believe UPCARE E2E transcends other technology focused solutions in the industry since it combines all the capabilities needed for lab outreach success. It takes an integrated approach of strategy, people, process and technology to make a lab outreach program profitable. Up until now, labs have had to assemble all the parts themselves. UPCARE E2E delivers an end to end solution using techniques and expertise from highly successful lab outreach programs."

UPCARE E2E will specifically draw on the knowledge and experience of its lab managers, technology experts and executives responsible for the success at MGHS and other programs. Services are designed to assist UPCARE Technology's clients in developing new lab outreach programs or to improve the performance of existing programs.

The company has a senior team of experts and consultants who have successfully led lab outreach and lab operations for more than 30 organizations such as Quest/MetPath, UniLab, National Health Laboratory and Laboratory Corporation of America. Combined with UPCARE's clinical technology integration team and on-going partnership with Hunter Consulting, a specialty lab consulting firm, UPCARE has one of the industry's most powerful multi-disciplinary teams serving the laboratory segment.

In lin
'/>"/>

SOURCE UPCARE Technology, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Vedic vibration technology- the new cure for arthritis
2. Biotechnology industry expected to grow into a three billion dollar industry by 2002
3. Biotechnology on the lead
4. New Technology In MRI Scan Help Test Brain Cancer Therapy
5. New technology to decipher neural connections dealing with heredity and environment
6. Emergence Of New Gene Scanning Technology In Disease Research
7. CoQ10 bioavailability increased by Nanotechnology
8. Developing a new vaccine using a new technology
9. Scientists Develop New Technology To Find About Human Ancestors’ Teet
10. T-waves to sweep over imaging technology
11. Nanotechnology Revolution To Be Spearheaded By European Union
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)...Ala., Dec. 2 Southern... organization that conducts basic and applied rese...d development, advanced engineering, environmental...has been awarded a subcontract from Black & Ve...e,s Biological Threat Reduction Program (BTRP) in ...
(Date:12/2/2008)...Dec. 2 What is the T Zo...or mouth. Touching your mucous membranes is how m...k. Touching the T Zone is also referred to as dir...e picking, nail biting and many other descriptors.... habit you will help reduce flu and flu-like illne...
(Date:12/2/2008)...SANTA MONICA, Calif., Dec. 2 /PRNewswire-USNewswir...sent a letter today to President-elect Obama urgin...h care affordable and available by allowing any Am...oup warned Obama that a proposal pushed by health ...y private health insurance policies "amounts only ...
(Date:12/2/2008)...e Health Initiative Will Expand to 70 Cities and R... As the first investment...Johnson Foundation (RWJF) has awarded grants of up...y that will serve as leading sites for its most am...y epidemic. , , Healthy Kids, Healthy Comm...
Breaking Medicine News(10 mins):Health News:Southern Research Wins $37 Million Black & Veatch Sub-Contract for Biological Threat Reduction Program 2Health News:Southern Research Wins $37 Million Black & Veatch Sub-Contract for Biological Threat Reduction Program 3Health News:Dr. Will Sawyer and Henry the Hand Champion Handwasher Have Discovered How to PREVENT the Flu and Common Cold!! DO NOT TOUCH the T Zone! 2Health News:Consumer Watchdog to Obama: Open Medicare to All Americans 2Health News:Consumer Watchdog to Obama: Open Medicare to All Americans 3Health News:Robert Wood Johnson Foundation Awards Grants to Nine Communities In Launch of $44 Million National Program to Reverse Childhood Obesity 2Health News:Robert Wood Johnson Foundation Awards Grants to Nine Communities In Launch of $44 Million National Program to Reverse Childhood Obesity 3Health News:Robert Wood Johnson Foundation Awards Grants to Nine Communities In Launch of $44 Million National Program to Reverse Childhood Obesity 4
...isphosphonates are at an increased risk of jaw or ...nates are used to treat cancer-related bone lesio...duced bone density. Several recent studies have f...of intravenous bisphosphonates and osteonecrosis o...
...ople have been bitten and injured by a jackal in B...abies vaccines in the government hospitals to trea... has attacked and injured villagers - including wo...villages under the Manjhagarh block of the distric...
...al progress in curbing the spread of polio with ju...r compared to 676 last year, says WHO. Of the 8...m Uttar Pradesh and 17 from Bihar, it says. 'The...polio in 2007 is 213 compared with 585 for the sam...
...n Pakistan, evoking mixed reactions. <brThei...omething extraordinary. Then the Lahore High Cour...omes as a pleasant surprise is the decision of the... Court to release them on bail and hear their app...
Other Medicine News:Health News:Bisphosphonate Increases the Risk of Jaw Bone Deterioration 2Health News:India Records Substantial Decline in Polio Cases 2Health News:Same Sex Pair Get Relief in Pakistan 2
(Date:12/1/2008)...e study shows the Prox1 gene is a two-way switch t...ells to be reprogrammed so that they lose their id...s , , MEMPHIS, Tenn., Dec. 1 /PRNewswire-US...search Hospital have discovered that a certain dif...entity that it requires the constant expression of...
(Date:12/1/2008)...STGARD, Denmark, December 1 /PRNewswire-FirstCall/...07 with the intent to procure an MVA-based,third...ernment Services,Canada, on behalf of the Canadia...ontract to Bavarian Nordic for the delivery of IMV... to use IMVAMUNE(R) as part of the,country,s bio-...
(Date:12/1/2008)...GO, Dec. 1 Vical Incorpo...t of a $1.0 million milestone payment from Merck &... of a Phase I clinical trial of an investigational...vaccine is based on Vical,s DNA gene delivery tech...riptase (hTERT). hTERT is the subject of separate ...
(Date:11/28/2008)...RLITZ, Germany, November 28 German...eadership in specialized HIV monitoring and,AIDS ...merging countries. In,the year 2008, 2.5 million ...le, robust and highly affordable "CyFlow" system, ...ing with HIV/AIDS. Due to introduction of the,Par...
Breaking Medicine Technology:Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 2The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2Fantastic photographs of fluorescent fish 4890 1Old and new therapies combine to tackle atherosclerosis 7697 1Old and new therapies combine to tackle atherosclerosis 7697 2Old and new therapies combine to tackle atherosclerosis 7697 3Water purification down the nanotubes 7695 1Water purification down the nanotubes 7695 2Cadence Pharmaceuticals Updates Omigard 28TM 29 Clinical Timeline 3058 1Cadence Pharmaceuticals Updates Omigard 28TM 29 Clinical Timeline 3058 2Cadence Pharmaceuticals Updates Omigard 28TM 29 Clinical Timeline 3058 3Cadence Pharmaceuticals Updates Omigard 28TM 29 Clinical Timeline 3058 4
...o Company Oncology Programs to be Presented, SOUTH...-FirstCall/ -- Cytokinetics, Incorporated announce...data will be,presented at the 2007 Annual Meeting ...ACR) to be held from April 14- 18, 2007 in,Los Ang...cology,programs at Cytokinetics and will present d...
...--(BUSINESS WIRE)--Apr 9, 2007 -,GlaxoSmithKline (...DLR) today announced data from Study 767905/014 an...rogram for,alvimopan (Entereg/Entrareg(R))., Study...(12,month) study, was designed to evaluate the lon... twice daily in patients taking,opioids for chroni...
Other Medicine Technology:Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 2Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 3Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 4Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 5Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 6Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 7GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 2GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 3GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 4GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 5GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 6GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 7
Wilbrandt-binkhorst irrigating cannula.
Binkhorst, length 18 mm.
Wilbrandt-Binkhorst Cannula have a smooth blunt tip end opening.
Army navy retractor set.
Medicine Products: